Alain Algazi, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address550 16th. Street, #6802
San Francisco CA 94158
Phone415-353-7552
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    UCLA School of Medicine2004
    UCLA Medical CenterResidency2007Internal Medicine
    UCSFFellowship2010Hematology-Oncology

    Collapse Overview 
    Collapse Overview
    Dr. Alain Algazi is a specialist in medical treatment – such as chemotherapy and immunotherapy – for patients with head and neck cancers, including head and neck squamous cell carcinoma, thyroid cancers and salivary gland cancers. He leads UCSF's program in medical therapy for head and neck cancers, and chairs the head and neck cancer research committee.

    In research, Algazi conducts clinical trials – studies that evaluate new therapies for head and neck cancers with an emphasis on approaches to improving the chances of long term remission in patients with incurable cancer using immunotherapy. He has also served the national study chair for clinical trials that give patients access to new medications and that provide new approaches of administering existing medications to improve their efficacy.

    Algazi earned his medical degree from the David Geffen School of Medicine at UCLA and completed a residency in internal medicine at Ronald Reagan UCLA Medical Center. He completed a fellowship in hematology-oncology at UCSF.

    Algazi is a member of the American Society of Clinical Oncology, Society for Immunotherapy for Cancer and American Association for Cancer Research.

    To reach Dr. Alain Algazi, please contact the head and neck medical oncology practice at (415) 353-9900.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers. Cancer. 2024 Jan 23. Algazi AP, Moon J, Lao CD, Chmielowski B, Kendra KL, Lewis KD, Gonzalez R, Kim K, Godwin JE, Curti BD, Latkovic-Taber M, Lomeli SH, Gufford BT, Scumpia PO, Lo RS, Othus M, Ribas A. PMID: 38261444.
      View in: PubMed   Mentions:    Fields:    
    2. Carboplatin and paclitaxel after anti-PD-1 or anti-PD-L1 antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck. Head Neck. 2024 Feb; 46(2):321-327. Humphries A, Zhou CJ, Welsh M, Lem M, Kang H, Algazi AP. PMID: 37997549.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. The neutrophil-to-lymphocyte ratio in salivary gland cancers treated with pembrolizumab. Head Neck. 2024 Jan; 46(1):129-137. Lee RH, Truong A, Wu X, Kang H, Algazi AP, El-Sayed IH, George JR, Heaton CM, Ryan WR, Ha PK, Wai KC. PMID: 37897202.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    4. Treatment Modality Impact on Patient-Reported Quality of Life in Human Papilloma Virus-Associated Oropharyngeal Carcinoma. Laryngoscope. 2024 Apr; 134(4):1687-1695. Plonowska-Hirschfeld KA, Gulati A, Stephens EM, Ochoa E, Xu MJ, Ha PK, Heaton CM, Yom SS, Chan JW, Algazi A, Kang H, Ryan WR. PMID: 37767815.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    5. A prospective evaluation of neck and shoulder function following treatments of early-stage human papillomavirus-associated oropharynx cancer. Clin Otolaryngol. 2023 Sep; 48(5):756-765. Gulati A, Plonowska-Hirschfeld K, Stephens EM, Kansara S, Zebolsky AL, Ochoa E, Xu MJ, Ha PK, Heaton CM, Yom SS, Chan JW, Algazi AP, Kang H, Ryan WR. PMID: 37212448.
      View in: PubMed   Mentions:    Fields:    
    6. Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell. 2023 03 16; 186(6):1127-1143.e18. Rahim MK, Okholm TLH, Jones KB, McCarthy EE, Liu CC, Yee JL, Tamaki SJ, Marquez DM, Tenvooren I, Wai K, Cheung A, Davidson BR, Johri V, Samad B, O'Gorman WE, Krummel MF, van Zante A, Combes AJ, Angelo M, Fong L, Algazi AP, Ha P, Spitzer MH. PMID: 36931243; PMCID: PMC10348701.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    7. Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study. Cancer. 2023 04 15; 129(8):1195-1204. Oh DY, Algazi A, Capdevila J, Longo F, Miller W, Chun Bing JT, Bonilla CE, Chung HC, Guren TK, Lin CC, Motola-Kuba D, Shah M, Hadoux J, Yao L, Jin F, Norwood K, Lebellec L. PMID: 36748723.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    8. Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2023 02 01; 29(3):560-570. Aggarwal C, Saba NF, Algazi A, Sukari A, Seiwert TY, Haigentz M, Porosnicu M, Bonomi M, Boyer J, Esser MT, Cheng LI, Agrawal S, Jennings EC, Durham NM, Fraser K, Lissa D, Gong M, Ceaicovscaia N, Gascó Hernández A, Kumar R. PMID: 36455147; PMCID: PMC9890138.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    9. Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. Ann Oncol. 2023 03; 34(3):251-261. Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Kim SB, Ho GF, Caguioa PB, Ngamphaiboon N, Ho C, Aziz MASA, Ng QS, Yen CJ, Soparattanapaisarn N, Ngan RK, Kho SK, Tiambeng MLA, Yun T, Sriuranpong V, Algazi AP, Cheng A, Massarelli E, Swaby RF, Saraf S, Yuan J, Siu LL. PMID: 36535566.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    10. Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101). Clin Cancer Res. 2022 12 01; 28(23):5079-5087. Babiker H, Borazanci E, Subbiah V, Agarwala S, Algazi A, Schachter J, Lotem M, Maurice-Dror C, Hendler D, Rahimian S, Minderman H, Haymaker C, Mahadevan D, Bernatchez C, Murthy R, Hultsch R, Kaplan N, Woodhead G, Hennemeyer C, Chunduru S, Anderson PM, Diab A, Puzanov I. PMID: 35917516.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    11. Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors. Cancer. 2023 01 01; 129(1):71-81. Naing A, Algazi AP, Falchook GS, Creelan BC, Powderly J, Rosen S, Barve M, Mettu NB, Triozzi PL, Hamm J, Zhou G, Walker C, Dong Z, Patel MR. PMID: 36309837; PMCID: PMC10092291.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    12. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12. Immunity. 2022 Sep 13; 55(9):1749. Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ. PMID: 36103861.
      View in: PubMed   Mentions: 5     Fields:    
    13. Melanoma risk during immunomodulating treatment. Melanoma Res. 2022 12 01; 32(6):411-418. Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S. PMID: 35993892.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity. Mol Cancer Res. 2022 06 03; 20(6):983-995. Han M, Nguyen B, Lee JY, Browning E, Zhang J, Mukhopadhyay A, Gujar R, Salazar J, Hermiz R, Svenson L, Rolig AS, Redmond WL, Algazi AP, Daud AI, Canton DA, Twitty CG. PMID: 35302641.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    15. Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity. Mol Ther Oncolytics. 2022 Jun 16; 25:174-188. Lee JY, Nguyen B, Mukhopadhyay A, Han M, Zhang J, Gujar R, Salazar J, Hermiz R, Svenson L, Browning E, Lyerly HK, Canton DA, Fisher D, Daud A, Algazi A, Skitzki J, Twitty CG. PMID: 35592387; PMCID: PMC9092072.
      View in: PubMed   Mentions: 1  
    16. Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial. Clin Cancer Res. 2022 03 15; 28(6):1157-1166. Cohen EEW, Nabell L, Wong DJ, Day T, Daniels GA, Milhem M, Deva S, Jameson M, Guntinas-Lichius O, Almubarak M, Strother M, Whitman E, Chisamore M, Obiozor C, Bagulho T, Gomez-Romo J, Guiducci C, Janssen R, Gamelin E, Algazi AP. PMID: 34965944.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    17. Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clin Cancer Res. 2022 Mar 01; 28(5):903-914. Taylor MH, Betts CB, Maloney L, Nadler E, Algazi A, Guarino MJ, Nemunaitis J, Jimeno A, Patel P, Munugalavadla V, Tao L, Adkins D, Goldschmidt JH, Cohen EEW, Coussens LM. PMID: 34862248; PMCID: PMC9311322.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    18. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021 12; 22(12):1692-1704. Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, Moschos SJ, Atkins MB, Lewis K, Postow MA, Thomas RP, Glaspy J, Jang S, Khushalani NI, Pavlick AC, Ernstoff MS, Reardon DA, Kudchadkar R, Tarhini A, Chung C, Ritchings C, Durani P, Askelson M, Puzanov I, Margolin KA. PMID: 34774225; PMCID: PMC9328029.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCTClinical Trials
    19. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro Oncol. 2021 11 02; 23(11):1961-1973. Tawbi HA, Forsyth PA, Hodi FS, Lao CD, Moschos SJ, Hamid O, Atkins MB, Lewis K, Thomas RP, Glaspy JA, Jang S, Algazi AP, Khushalani NI, Postow MA, Pavlick AC, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Tarhini AA, Sumbul A, Rizzo JI, Margolin KA. PMID: 33880555; PMCID: PMC8563325.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    20. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell. 2021 10 11; 39(10):1375-1387.e6. Wang Y, Liu S, Yang Z, Algazi AP, Lomeli SH, Wang Y, Othus M, Hong A, Wang X, Randolph CE, Jones AM, Bosenberg MW, Byrum SD, Tackett AJ, Lopez H, Yates C, Solit DB, Ribas A, Piva M, Moriceau G, Lo RS. PMID: 34416167; PMCID: PMC9126729.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimals
    21. Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nat Commun. 2021 Aug 12; 12(1):5022. Ribas A, Algazi A, Ascierto PA, Butler MO, Chandra S, Gordon M, Hernandez-Aya L, Lawrence D, Lutzky J, Miller WH, Campbell KM, Delafont B, Marshall S, Mueller N, Robert C. PMID: 34385448; PMCID: PMC8360951.
      View in: PubMed   Mentions:    Fields:    
    22. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nat Commun. 2020 12 07; 11(1):6262. Ribas A, Algazi A, Ascierto PA, Butler MO, Chandra S, Gordon M, Hernandez-Aya L, Lawrence D, Lutzky J, Miller WH, Campbell KM, Delafont B, Marshall S, Mueller N, Robert C. PMID: 33288749; PMCID: PMC7721806.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    23. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020 10; 26(10):1564-1568. Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. PMID: 33020646; PMCID: PMC8063889.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    24. Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Ann Surg Oncol. 2020 Oct; 27(11):4122-4130. Levine LS, Mahuron KM, Tsai KK, Wu C, Mattis DM, Pauli ML, Oglesby A, Lee JC, Spitzer MH, Krummel MF, Algazi AP, Rosenblum MD, Alvarado M, Daud AI. PMID: 32488521; PMCID: PMC8317618.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    25. Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. Clin Cancer Res. 2020 06 15; 26(12):2827-2837. Algazi AP, Twitty CG, Tsai KK, Le M, Pierce R, Browning E, Hermiz R, Canton DA, Bannavong D, Oglesby A, Francisco M, Fong L, Pittet MJ, Arlauckas SP, Garris C, Levine LP, Bifulco C, Ballesteros-Merino C, Bhatia S, Gargosky S, Andtbacka RHI, Fox BA, Rosenblum MD, Daud AI. PMID: 32376655; PMCID: PMC9354653.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    26. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 04; 31(4):532-540. Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, Fong L, Levine LP, Franco M, Oglesby A, Ballesteros-Merino C, Bifulco CB, Fox BA, Bannavong D, Talia R, Browning E, Le MH, Pierce RH, Gargosky S, Tsai KK, Twitty C, Daud AI. PMID: 32147213.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    27. Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. Cancer Immunol Res. 2020 02; 8(2):246-254. Greaney SK, Algazi AP, Tsai KK, Takamura KT, Chen L, Twitty CG, Zhang L, Paciorek A, Pierce RH, Le MH, Daud AI, Fong L. PMID: 31852717; PMCID: PMC7002232.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCellsCTClinical Trials
    28. Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers. Am J Clin Dermatol. 2019 Dec; 20(6):781-796. Oglesby A, Algazi AP, Daud AI. PMID: 31228012.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    29. A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma. Pigment Cell Melanoma Res. 2019 07; 32(4):603-606. Algazi AP, Rotow J, Posch C, Ortiz-Urda S, Pelayo A, Munster PN, Daud A. PMID: 30801911.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    30. Treatment modality impact on quality of life for human papillomavirus-associated oropharynx cancer. Laryngoscope. 2020 02; 130(2):E48-E56. Xu MJ, Plonowska KA, Gurman ZR, Humphrey AK, Ha PK, Wang SJ, El-Sayed IH, Heaton CM, George JR, Yom SS, Algazi AP, Ryan WR. PMID: 30919470.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    31. Ultraviolet light-related DNA damage mutation signature distinguishes cutaneous from mucosal or other origin for head and neck squamous cell carcinoma of unknown primary site. Head Neck. 2019 06; 41(6):E82-E85. Chan JW, Yeh I, El-Sayed IH, Algazi AP, Glastonbury CM, Ha PK, Yom SS, van Zante A. PMID: 30633411.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    32. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019 01; 107:142-152. Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R. PMID: 30576970.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansCTClinical Trials
    33. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12. Immunity. 2018 12 18; 49(6):1148-1161.e7. Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ. PMID: 30552023; PMCID: PMC6301092.
      View in: PubMed   Mentions: 390     Fields:    Translation:HumansAnimalsCells
    34. Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. Am J Clin Oncol. 2018 Nov; 41(11):1083-1088. Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong RL, Le Tourneau C, Day D, Varga A, Elez E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B. PMID: 29462123; PMCID: PMC6211783.
      View in: PubMed   Mentions: 71     Fields:    
    35. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018 Aug 23; 379(8):722-730. Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K. PMID: 30134131; PMCID: PMC8011001.
      View in: PubMed   Mentions: 512     Fields:    Translation:HumansCTClinical Trials
    36. Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma. J Otolaryngol Head Neck Surg. 2018 Apr 25; 47(1):28. Xu MJ, Wu TJ, van Zante A, El-Sayed IH, Algazi AP, Ryan WR, Ha PK, Yom SS. PMID: 29695289; PMCID: PMC5922301.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    37. Major prognostic factors for recurrence and survival independent of the American Joint Committee on Cancer eighth edition staging system in patients with cutaneous squamous cell carcinoma treated with multimodality therapy. Head Neck. 2018 07; 40(7):1406-1414. Xu MJ, Lazar AA, Garsa AA, Arron ST, Ryan WR, El-Sayed IH, George JR, Algazi AP, Heaton CM, Ha PK, Yom SS. PMID: 29524273.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    38. High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018 01 18; 553(7688):347-350. Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A. PMID: 29320474; PMCID: PMC5773412.
      View in: PubMed   Mentions: 148     Fields:    Translation:HumansCells
    39. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. Pigment Cell Melanoma Res. 2018 01; 31(1):110-114. Algazi AP, Esteve-Puig R, Nosrati A, Hinds B, Hobbs-Muthukumar A, Nandoskar P, Ortiz-Urda S, Chapman PB, Daud A. PMID: 28921907; PMCID: PMC8049535.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    40. Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid). Immunotherapy. 2017 12; 9(16):1309-1321. Canton DA, Shirley S, Wright J, Connolly R, Burkart C, Mukhopadhyay A, Twitty C, Qattan KE, Campbell JS, Le MH, Pierce RH, Gargosky S, Daud A, Algazi A. PMID: 29064334.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimals
    41. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. J Clin Oncol. 2017 Dec 20; 35(36):4050-4056. Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, Thanigaimani P, Cheng JD, Hansen AR. PMID: 28837405.
      View in: PubMed   Mentions: 204     Fields:    Translation:HumansCTClinical Trials
    42. Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight. 2017 Jul 20; 2(14). Loo K, Tsai KK, Mahuron K, Liu J, Pauli ML, Sandoval PM, Nosrati A, Lee J, Chen L, Hwang J, Levine LS, Krummel MF, Algazi AP, Pampaloni M, Alvarado MD, Rosenblum MD, Daud AI. PMID: 28724802; PMCID: PMC5518562.
      View in: PubMed   Mentions: 33     Fields:    
    43. Are PD-1 antibodies safe for use in metastatic uveal melanoma? Melanoma Manag. 2017 May; 4(2):79-82. Tsai KK, Algazi AP. PMID: 30190908; PMCID: PMC6094660.
      View in: PubMed   Mentions:
    44. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017 05; 5(5):417-424. Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A. PMID: 28411193; PMCID: PMC5749922.
      View in: PubMed   Mentions: 264     Fields:    Translation:HumansCellsCTClinical Trials
    45. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Br J Cancer. 2017 Apr 25; 116(9):1141-1147. Nosrati A, Tsai KK, Goldinger SM, Tumeh P, Grimes B, Loo K, Algazi AP, Nguyen-Kim TDL, Levesque M, Dummer R, Hamid O, Daud A. PMID: 28324889; PMCID: PMC5418446.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCTClinical Trials
    46. Head and neck cancer in 2016: A watershed year for improvements in treatment? Nat Rev Clin Oncol. 2017 Feb; 14(2):76-78. Algazi AP, Grandis JR. PMID: 27922045.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    47. A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. Clin Cancer Res. 2017 04 15; 23(8):1910-1919. Rosen LS, Goldman JW, Algazi AP, Turner PK, Moser B, Hu T, Wang XA, Tuttle J, Wacheck V, Wooldridge JE, Banck M. PMID: 27803065.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    48. Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst. 2017 01; 109(1). Faden DL, Algazi A. PMID: 27671684.
      View in: PubMed   Mentions: 21     Fields:    
    49. Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. J Immunother Cancer. 2016; 4:58. Tsai KK, Pampaloni MH, Hope C, Algazi AP, Ljung BM, Pincus L, Daud AI. PMID: 27660712; PMCID: PMC5028983.
      View in: PubMed   Mentions: 17     Fields:    
    50. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016 Nov 15; 122(21):3344-3353. Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ. PMID: 27533448; PMCID: PMC5767160.
      View in: PubMed   Mentions: 163     Fields:    Translation:Humans
    51. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016 Nov 15; 122(21):3354-3362. Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA. PMID: 27533633; PMCID: PMC5134420.
      View in: PubMed   Mentions: 112     Fields:    Translation:Humans
    52. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016 09 01; 126(9):3447-52. Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD, Algazi AP, Pampaloni MH, Lobach IV, Hwang J, Pierce RH, Gratz IK, Krummel MF, Rosenblum MD. PMID: 27525433; PMCID: PMC5004965.
      View in: PubMed   Mentions: 267     Fields:    Translation:HumansCells
    53. NCCN Guidelines Insights: Melanoma, Version 3.2016. J Natl Compr Canc Netw. 2016 08; 14(8):945-58. Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, DiMaio D, Fields RC, Fleming MD, Gastman B, Gonzalez R, Guild V, Johnson D, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A. PMID: 27496110.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    54. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Apr 19; 315(15):1600-9. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C. PMID: 27092830.
      View in: PubMed   Mentions: 477     Fields:    Translation:HumansCTClinical Trials
    55. Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Apr; 14(4):450-73. Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, DiMaio D, Ernstoff M, Fields RC, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A. PMID: 27059193.
      View in: PubMed   Mentions: 138     Fields:    Translation:Humans
    56. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016 Mar 10; 34(8):871-8. Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT. PMID: 26811525.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansCTClinical Trials
    57. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol. 2015 Nov; 151(11):1206-1212. Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S. PMID: 26222619; PMCID: PMC5061067.
      View in: PubMed   Mentions: 185     Fields:    Translation:Humans
    58. Induction Hedgehog pathway inhibition followed by combined-modality radiotherapy for basal cell carcinoma. Br J Dermatol. 2015 Aug; 173(2):544-6. Raleigh DR, Algazi A, Arron ST, Neuhaus IM, Yom SS. PMID: 25702621.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    59. The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. Br J Cancer. 2015 Apr 14; 112(8):1326-31. Algazi AP, Cha E, Ortiz-Urda SM, McCalmont T, Bastian BC, Hwang J, Pampaloni MH, Behr S, Chong K, Cortez B, Quiroz A, Coakley F, Liu S, Daud AI. PMID: 25867272; PMCID: PMC4402449.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    60. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. PMID: 25665005; PMCID: PMC4930244.
      View in: PubMed   Mentions: 274     Fields:    Translation:HumansAnimalsCells
    61. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell. 2015 Feb 09; 27(2):240-56. Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. PMID: 25600339; PMCID: PMC4326539.
      View in: PubMed   Mentions: 173     Fields:    Translation:HumansCells
    62. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014 Dec; 71(6):1102-1109.e1. Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S. PMID: 25440439; PMCID: PMC4254519.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    63. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014 Nov 20; 32(33):3697-704. Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. PMID: 25287827; PMCID: PMC4226803.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCTClinical Trials
    64. Melanoma immunotherapy. Cancer Biol Ther. 2014 Jun 01; 15(6):665-74. Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S. PMID: 24651672; PMCID: PMC4049781.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    65. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11; 369(2):134-44. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. PMID: 23724846; PMCID: PMC4126516.
      View in: PubMed   Mentions: 1602     Fields:    Translation:HumansCTClinical Trials
    66. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov; 13(11):1087-95. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. PMID: 23051966.
      View in: PubMed   Mentions: 327     Fields:    Translation:HumansCTClinical Trials
    67. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 11 01; 367(18):1694-703. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. PMID: 23020132; PMCID: PMC3549295.
      View in: PubMed   Mentions: 1161     Fields:    Translation:HumansCellsCTClinical Trials
    68. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer. 2012 Jan 03; 106(1):85-91. Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI. PMID: 22127285; PMCID: PMC3251861.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    69. NRAS-mutant melanoma: response to chemotherapy. Arch Dermatol. 2011 May; 147(5):626-7. Soon CW, Algazi AP, Cha EN, Webb EM, Daud AI. PMID: 21576590.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    70. Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. Br J Cancer. 2010 Nov 09; 103(10):1548-53. DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, Floren L, Hwang J, Weber J, Sondak VK, Daud AI. PMID: 20924376; PMCID: PMC2990578.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    71. Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res. 2010 Aug 17; 2:197-211. Algazi AP, Soon CW, Daud AI. PMID: 21188111; PMCID: PMC3004577.
      View in: PubMed   Mentions: 23  
    72. New horizons in melanoma treatment: targeting molecular pathways. Ochsner J. 2010; 10(2):93-8. Soon CW, Algazi AP, Cha EN, Daud AI. PMID: 21603363; PMCID: PMC3096197.
      View in: PubMed   Mentions: 1  
    73. Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics. 2009 Jul; 6(3):587-97. Algazi AP, Kadoch C, Rubenstein JL. PMID: 19560747; PMCID: PMC4942275.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    74. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med. 2008 May 01; 6:22. Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A. PMID: 18452610; PMCID: PMC2412852.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCellsCTClinical Trials
    75. Lesions of frontal cortex diminish the auditory mismatch negativity. Electroencephalogr Clin Neurophysiol. 1994 Nov; 91(5):353-62. Alho K, Woods DL, Algazi A, Knight RT, Näätänen R. PMID: 7525232.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    76. Processing of auditory stimuli during auditory and visual attention as revealed by event-related potentials. Psychophysiology. 1994 Sep; 31(5):469-79. Alho K, Woods DL, Algazi A. PMID: 7972601.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    77. Stages of auditory feature conjunction: an event-related brain potential study. J Exp Psychol Hum Percept Perform. 1994 Feb; 20(1):81-94. Woods DL, Alho K, Algazi A. PMID: 8133226.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    78. Intermodal selective attention: evidence for processing in tonotopic auditory fields. Psychophysiology. 1993 May; 30(3):287-95. Woods DL, Alho K, Algazi A. PMID: 8497558.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    79. Intermodal selective attention. I. Effects on event-related potentials to lateralized auditory and visual stimuli. Electroencephalogr Clin Neurophysiol. 1992 May; 82(5):341-55. Woods DL, Alho K, Algazi A. PMID: 1374703.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    80. Intermodal selective attention. II. Effects of attentional load on processing of auditory and visual stimuli in central space. Electroencephalogr Clin Neurophysiol. 1992 May; 82(5):356-68. Alho K, Woods DL, Algazi A, Näätänen R. PMID: 1374704.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    81. Brain potential signs of feature processing during auditory selective attention. Neuroreport. 1991 Apr; 2(4):189-92. Woods DL, Alho K, Algazi A. PMID: 1893092.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    Alain's Networks
    Concepts (244)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (72)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.